BioSpace News Archive

Ginkgo Bioworks announced it is joining efforts with Penn State University to integrate its biosurveillance capabilities into the university’s research of 58 wildlife species for SARS-CoV-2 to monitor potential spillover to humans.

908 Devices Inc., a pioneer of handheld and desktop devices for chemical and biochemical analysis, announced it will report financial results for the third quarter 2023 before market open on Tuesday, November 7, 2023.

Bristol Myers Squibb announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 antagonist, for the treatment of progressive pulmonary fibrosis, a devastating, life-threatening illness.

Neurocentrx announced positive topline results from its Phase 1 clinical study of KET-IR, its novel oral ketamine immediate-release formulation to treat major mental health conditions, including treatment-resistant depression.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that it plans to release financial results for the third quarter ended September 30, 2023 on November 7, 2023.

ZYUS Life Sciences Corporation, a Canadian-based life sciences company leading scientific research and global development of innovative cannabinoid-based pharmaceutical drug products, is pleased to announce that Tim Miller is joining the Company as Director of Investor Relations and Capital Markets, effective November 1, 2023.

NeuroTherapia, Inc. today announced the presentation of clinical data from its Phase 1b clinical trial of NTRX-07, an oral, small molecule CB2-targeting therapy in development for the treatment of Alzheimer’s disease (AD), in healthy volunteers and a subset of patients with mild cognitive impairment or early AD, at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, taking place in Boston, Mass., Oct. 24-27, 2023.

SAB Biotherapeutics , Inc. (Nasdaq: SABS ), today announced that Michael G. King Jr. has been named Chief Financial Officer. SAB is a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a fully-human anti-thymocyte immunoglobulin (hIgG) that may delay the onset or progression of type 1 diabetes (T1D).

Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children’s Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis.

Citius Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement, dated October 23, 2023, for a proposed merger of TenX and Citius Pharma’s wholly owned oncology subsidiary that will continue as a public company listed on the Nasdaq exchange.